Abstract:With the broad application of cancer immunotherapies such as immune checkpoint inhibitors in multiple cancer types, the immunological landscape in the tumor microenvironment (TME) has become enormously important for determining the optimal cancer treatment. Tumors can be immunologically divided into two categories: inflamed and non-inflamed based on the extent of immune cell infiltration and their activation status. In general, immunotherapies are preferable for the inflamed tumors than for non-inflamed tumors. Regulatory T cells (Tregs), an immunosuppressive subset of CD4 + T cells, play an essential role in maintaining self-tolerance and immunological homeostasis. In tumor immunity, Tregs compromise immune surveillance against cancer in healthy individuals and impair the antitumor immune response in tumor-bearing hosts. Tregs, therefore, accelerate immune evasion by tumor cells, leading to tumor development and progression in various types of cancer. Therefore, Tregs are considered to be a crucial therapeutic target for cancer immunotherapy. Abundant Tregs are observed in the TME in many types of cancer, both in inflamed and non-inflamed tumors. Diverse mechanisms of Treg accumulation, activation, and survival in the TME have been uncovered for different tumor types, indicating the importance of understanding the mechanism of Treg infiltration in each patient when selecting the optimal Treg-targeted therapy. Here, we review recent advances in the understanding of mechanisms leading to Treg abundance in the TME to optimize Treg-targeted therapy. Furthermore, in addition to the conventional strategies targeting cell surface molecules predominantly expressed by Tregs, reagents targeting molecules and signaling pathways specifically employed by Tregs for infiltration, activation, and survival in each tumor type are illustrated as novel Treg-targeted therapies. The effectiveness of immune precision therapy depends on conditions in the TME of each cancer patient.

Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Targeting tumor-infiltrating tregs for improved antitumor responses

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Regulatory T cells in tumor immunity

Regulatory T cells in immune checkpoint blockade antitumor therapy

Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

Regulatory T‐cell development in the tumor microenvironment

Antibody-based Cancer Immunotherapy by Targeting Regulatory T Cells

Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?

Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition

Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review

Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy

Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?

Tumor-infiltrating Regulatory T Cells: Origins and Features

Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy